Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment

Reuters

2025/05/16

Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535357053"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535357053\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535357053?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 11:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535357053","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-16 11:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL747RlM:1","article_id":"2535357053","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535357053","pubTimestamp":1747367882,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets  by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","00460":"四环医药","BK1191":"制药","BK1593":"医美概念股","BK1600":"工业大麻"},"translate_title":"四环医药玄月宁®片获批双适应症乳腺癌治疗取得突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9},"content_text":"Sihuan Pharmaceutical's Xuanyuening® Tablets Approved for Dual Indications, Marking Breakthrough in Breast Cancer Treatment\n    \n\nSihuan Pharmaceutical Holdings Group Ltd. has announced the approval of Bireociclib tablets (trade name: Xuanyuening®) by the National Medical Products Administration on May 15, 2025. Developed by Xuanzhu Biopharmaceutical, this innovative Class 1 anti-tumor drug is indicated for dual conditions in HR+/HER2- breast cancer. The approval marks a significant advancement in breast cancer treatment, offering new hope to patients. Clinical trials tailored to Chinese patients demonstrated impressive results, with a median progression-free survival of up to 17.5 months in certain cases. Xuanzhu Bio is working to include Bireociclib in China's national medical insurance system, aiming to make the treatment more accessible and affordable. With breast cancer incidence rising, the market for CDK4/6 inhibitors in China is projected to reach tens of billions of yuan within five years, positioning Bireociclib tablets for significant market share due to their efficacy and dual indications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN89736) on May 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}